Sector News

Mylan Says It Is Opposed To Possible Teva Pharmaceuticals Merger

April 20, 2015
Life sciences
Generic drugmaker Mylan wants to put speculation of a possible merger with Teva Pharmaceuticals to rest. A potential deal, the company said, is “without sound industrial logic” and would have a hard time winning anti-trust clearances.
Mylan’s comments on Friday responded to reports from both Bloomberg and the Wall Street Journal that indicated Teva Pharmaceutical is considering a bid for the company. Speculation of a Teva bid pushed Mylan shares higher by over 4% on Friday, closing trading at a $32 billion market capitalization. Teva shares rose more than 2%.
“We have studied the potential combination of Mylan and Teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit,” Mylan executive chairman Robert Coury said in a statement.
“Further, there would be significant overlap in the companies’ businesses and we believe that it is unlikely that any such combination could obtain anti-trust regulatory clearances,” he added.
The company said on Friday it remains committed to a stand-alone business strategy, which includes a $28.9 billion unsolicited offer for competitor Perrigo , announced on April 8. “Today’s speculation has no impact whatsoever on this strategy,” said Koury, who added that the if a bid is made, the company will consider it in and what is in the best interest of its stakeholders,
Earlier in April, Mylan said it would pay $205 a share in cash and stock for Perrigo, without specifying an exact formula for its unsolicited takeover offer. With Perrigo in hand, Mylan said it would reach a critical mass in specialty brands, generics, over-the-counter (OTC) and nutritional products.
Mylan’s offer for Perrigo and signs Teva may enter the M&A fray, come at a time of heavy dealmaking in the fast-consolidating pharmaceutical sector.
In 2015 alone, Pfizer, Valeant Pharmaceuticals, Shire  and AbbVie have all cut multi-billion dollar takeover deals, leading to $126 billion in M&A in the first quarter, according to data provider Dealogic.
That comes on the heels of a banner year for healthcare M&A, even as a Department of Treasury freeze on so-called inversion transactions cancelled some of the year’s biggest merger efforts.
By Antoine Gara
Source: Forbes

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]